Details for Patent: 12,636,340
✉ Email this page to a colleague
Which drugs does patent 12,636,340 protect, and when does it expire?
Patent 12,636,340 protects KYPROLIS and is included in one NDA.
Protection for KYPROLIS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has three patent family members in three countries.
Drugs Protected by US Patent 12,636,340
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | Yes | 12,636,340*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | Yes | 12,636,340*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | AP | RX | Yes | Yes | 12,636,340*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,636,340
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Brazil | 112022021931 | ⤷ Start Trial | |||
| European Patent Office | 4143232 | ⤷ Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2021222524 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
